Nxera Deal History & Licensing Activity
Nxera is a life sciences. Over the past three years, Nxera has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (3 deals). The company currently has 1 active clinical trial, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
1
Top Modality
Small Molecules
Focus Area
Rare Disease
Nxera Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Nxera in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Agamree | Santhera | Small Molecules | Unknown | license | Apr 2026 |
Nxera Pipeline Focus
Therapeutic areas and modalities where Nxera is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Nxera Clinical Pipeline
Nxera has 1 active clinical trial across 1 development phase.
1
Phase 1
See How Your Asset Matches Nxera's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Nxera Licensing & Deal Activity
Nxera is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Nxera ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Nxera include Rare Disease (2 deals and trials), Immunology (1 deal and trial), and Solid Tumors (1 deal and trial). In terms of modality, Nxera has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Nxera and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Nxera's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.